Clinical management and follow-up of hypercholesterolemia among perinatally hiv-infected children enrolled in the PACTG 219C study

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 5, 2011, Pages 413-420

  Jacobson, Denise L ^a   Williams, Paige ^b   Tassiopoulos, Katherine ^c   Melvin, Ann ^d   Hazra, Rohan ^e   Farley, John ^f  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b Department of Biostatistics ^*  (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; children; cohort study; HIV; hypercholesterolemia

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; BILE ACID SEQUESTRANT; CHOLESTEROL; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; OMEGA 3 FATTY ACID; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PERINATAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; INCIDENCE; MALE; PREVALENCE;

EID: 80051552840     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822203f5     Document Type: Article

References (35)

1. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045-1052.
2. EL-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005;6:114-121. (Pubitemid 40425975)
3. Constans J, Pellegrin JL, Peuchant E, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest. 1994;24: 416-420. (Pubitemid 24201271)
4. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. J Am Med Assoc. 2003;289:2978-2982. (Pubitemid 37430100)
5. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med. 1991;90:154-162.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58. (Pubitemid 28190689)
7. Mulligan K. Abnormalities of body composition and lipids associated with HAART: pathogenesis, clinical manifestations, and case definitions. Presented at: 7th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, January 30-February 2, 2000. S20.
8. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr. 2000;23:35-43. (Pubitemid 30123263)
9. Melvin AJ, Lennon S, Mohan KM, et al. Metabolic abnormalities in HIV type 1-infected children treated and not treated with protease inhibitors. AIDS Res Hum Retroviruses. 2001;17:1117-1123. (Pubitemid 32881578)
10. Farley J, Gona P, Crain M, et al. Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C. J Acquir Immune Defic Syndr. 2005;38:480-487. (Pubitemid 40381558)
11. Lainka E, Oezbek S, Falck M, et al. Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy. Pediatrics. 2002;110:e56.
12. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS. 2004;18:1443-1451.
13. Bitnun A, Sochett E, Babyn P, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS. 2003;17:1319-1327. (Pubitemid 36819846)
14. Rhoads MP, Smith CJ, Tudor-Williams G, et al. Effects of highly active antiretroviral therapy on paediatric metabolite levels. HIV Med. 2006;7: 16-24.
15. Miller TL, Orav EJ, Lipshultz SE, et al. Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1. J Pediatr. 2008;153:491-497.
16. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr. 2006;41:453-460.
17. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIVinfected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705. (Pubitemid 29383638)
18. Cheseaux JJ, Jotterand V, Aebi C, et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. J Acquir Immune Defic Syndr. 2002;30:288-293. (Pubitemid 34774076)
19. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics. 2008;122:e129-e138.
20. Tassiopoulos K, Williams PL, Seage GR III, et al. Association of hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors, among perinatally HIV-infected children. J Acquir Immune Defic Syndr. 2008;47:607-614. (Pubitemid 351442017)
21. Flammer AJ, Vo NT, Ledergerber B, et al. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart. 2009;95: 385-390.
22. Sension M, Andrade Neto JL, Grinsztejn B, et al. Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr. 2009;51:153-162.
23. Colafigli M, Di Giambenedetto S, Bracciale L, et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. HIV Med. 2008;9:172-179. (Pubitemid 351283132)
24. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIVinfected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375: 396-407.
25. Fisher M, Moyle GJ, Shahmanesh M, et al. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2009;51:562-568.
26. Llibre JM, Domingo P, Palacios R, et al. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS. 2006;20:1407-1414. (Pubitemid 43948247)
27. Gonzalez-Tome MI, Amador JT, Pena MJ, et al. Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. BMC Infect Dis. 2008;8:144.
28. McComsey G, Bhumbra N, Ma JF, et al. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics. 2003;111:e275-e281.
29. Daniels SR, Greer FR, Committee on Nutrition. Lipid screening and cardiovascular health in childhood. Pediatrics. 2008;122:198-208.
30. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005;21:757-767. (Pubitemid 41434180)
31. Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6:572-578.
32. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
33. Vigano A, Aldrovandi GM, Giacomet V, et al. Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. Antivir Ther. 2005;10:917-924. (Pubitemid 43076343)
34. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. Prev Med. 1998;27:879-890. (Pubitemid 29010857)
35. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118:e1745-e1757. (Pubitemid 46397550)